Bp. Giroir et al., INHIBITION OF TUMOR-NECROSIS-FACTOR PREVENTS MYOCARDIAL DYSFUNCTION DURING BURN SHOCK, The American journal of physiology, 267(1), 1994, pp. 80000118-80000124
Tumor necrosis factor-alpha (TNF) is a pluripotent cytokine that media
tes many of the hemodynamic manifestations of endotoxic shock. To dete
rmine whether TNF is responsible for postburn myocardial dysfunction,
we compared cardiac function (Langendorff preparation) in 49 guinea pi
gs 18 h after thermal injury. Group 1 (n = 15) was sham burned; all re
maining animals received a 43% surface area burn under anesthesia. Gro
up 2 (n = 15) received lactated Ringer solution (LR, 4 ml . kg(-1). %b
urn(-1)). Group 3 (n = 9) received LR and drug vehicle. Group 4 (n = 1
0) received LR plus 1 mg of TNF inhibitor consisting of the human p80
TNF receptor linked to the Fc portion of human immunoglobulin G1, whic
h was shown to specifically bind and neutralize TNF secreted by guinea
pig peritoneal macrophages in vitro. Burn injury caused a significant
fall in left ventricular pressure (LVP, from 86 +/- 2 to 62 +/- 3 mmH
g, P < 0.05) and maximal rate of LVP rise (+) and fall(-) (+/-dP/dt(ma
x)) [from 1,365 +/- 42 to 1,109 +/- 44 mmHg/s (P < 0.05) and from 1,18
4 +/- 31 to 881 + 40 mmHg/s (P < 0.05), respectively], a decrease in t
ime to peak systolic LVP (from 111 +/- 2 to 102 +/- 2 ms, P < 0.05), a
nd a decrease in time to +dP/dt(max) (from 57 +/- 1 to 48 +/- 1 ms, P
< 0.05). TNF inhibition significantly improved all parameters of cardi
odynamic function: LVP, 79 +/- 2 mmHg; +/-dP/dt(max), 1,451 +/- 44 and
1,212 +/- 52 mmHg/s, respectively; time to peak systolic LVP, 99 +/-
2 ms; time to +dP/dt(max), 52 +/- 2 ms. In addition, TNF blockade rest
ored left ventricular performance, as indicated by improved LW, +dP/dt
(max), and -dP/dt(max) responses to increases in preload (P < 0.05) an
d to increases in coronary flow rate (P < 0.05). These data indicate t
hat TNF is a critical mediator of postburn cardiac dysfunction; inhibi
tion of TNF by novel immunobiologics may be useful therapy in burns an
d other TNF-mediated diseases.